Although there have been major advances in understanding the genetic basis of schizophrenia (SZ) and bipolar disorder (BD) using genome-wide association studies (GWAS), identifying disease causing functional variants in patients remains a problem. An exception is the finding of structural alterations, such as patient-specific copy number variants (CNVs), which have been found a sizeable minority of patients with SZ and autism spectrum disorders (ASD), especially do novo cases. Disease-associated SNPs identified in GWAS are usually not functional variants on their own, but are presumably in linkage disequilibrium (LD) with bona fide disease-causing functional mutations. However, identifying such variants is difficult, especially when associated SNPs are found in non-coding regions - deep within introns or in intergenic regions far removed from the nearest annotated genes, which has been a common theme in GWAS. A reasonable assumption, considering that significant LD is maintained for only ~10-20 kb, is that many disease-causing mutations are occurring in regulatory elements that are far removed from a candidate gene's coding region, such as distal enhancers, suppressors and promoters of non-coding RNAs. A feature of many regulatory elements is sequence conservation. However, sequence conservation alone is not sufficient to establish biological function and human-specific enhancer elements have been observed. What are the regulatory elements that control the regulation of genes involved in psychiatric disorders? Does genetic variation in these regions contribute to disease risk? Are the positive association signals identified in GWAS due to LD with these features? One strategy we successfully implemented in the initial grant period was to use a chromatin immunoprecipitation based method - ChIP-chip - as a screening tool to identify novel regulatory elements in SZ and BD candidate genes. The basic ChIP-chip strategy involves immunoprecipitation of chromatin using antibodies (Ab) to proteins, such as covalently modified histones, that bind to DNA and are enriched in regulatory domains. These regions can then be assayed for biological activity and, if such activity can be demonstrated, resequenced to identify rare patient-specific variants or SNPs that have higher allele frequencies in patients compared with controls. Such potential disease- causing variants can also be subjected to functional analysis to establish biological activity. However, ChIP-chip is limiting by the number of genes and amount of DNA that can be interrogated. A much more comprehensive analysis for regulatory domain screening is ChIP-Seq, the primary advantage of which is that it provides unbiased, genomewide coverage. Thus, ChIP-Seq has the potential to identify regulatory elements in all previously characterized candidate genes, as well as those identified in the future, providing researchers with biologically active sites that can be efficiently screened to identify patient-specific mutations. The ChIP-Seq approach will also be used to identify binding sites, throughout the entire human genome, of transcription factors relevant to SZ and BD pathophysiology.

Public Health Relevance

This proposal describes experiments that will help identify regions of the genome involved in regulating the expression of candidate genes for schizophrenia, bipolar disorder, autism spectrum disorders and other neuropsychiatric disorders. Understanding how these genes are regulated may lead to novel treatment strategies. Furthermore, mutations in these regulatory regions may be responsible for disease susceptibility in a subgroup of patients.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Molecular Neurogenetics Study Section (MNG)
Program Officer
Beckel-Mitchener, Andrea C
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
Schools of Medicine
United States
Zip Code
Chen, Jian; Lin, Mingyan; Hrabovsky, Anastasia et al. (2015) ZNF804A Transcriptional Networks in Differentiating Neurons Derived from Induced Pluripotent Stem Cells of Human Origin. PLoS One 10:e0124597
Lin, Mingyan; Zhao, Dejian; Hrabovsky, Anastasia et al. (2014) Heat shock alters the expression of schizophrenia and autism candidate genes in an induced pluripotent stem cell model of the human telencephalon. PLoS One 9:e94968
Rockowitz, Shira; Lien, Wen-Hui; Pedrosa, Erika et al. (2014) Comparison of REST cistromes across human cell types reveals common and context-specific functions. PLoS Comput Biol 10:e1003671
Lien, Wen-Hui; Polak, Lisa; Lin, Mingyan et al. (2014) In vivo transcriptional governance of hair follicle stem cells by canonical Wnt regulators. Nat Cell Biol 16:179-90
Belinsky, Glenn S; Rich, Matthew T; Sirois, Carissa L et al. (2014) Patch-clamp recordings and calcium imaging followed by single-cell PCR reveal the developmental profile of 13 genes in iPSC-derived human neurons. Stem Cell Res 12:101-18
Chen, Jian; Lin, Mingyan; Foxe, John J et al. (2013) Transcriptome comparison of human neurons generated using induced pluripotent stem cells derived from dental pulp and skin fibroblasts. PLoS One 8:e75682
Banaszynski, Laura A; Wen, Duancheng; Dewell, Scott et al. (2013) Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. Cell 155:107-20
Lin, Mingyan; Hrabovsky, Anastasia; Pedrosa, Erika et al. (2012) Allele-biased expression in differentiating human neurons: implications for neuropsychiatric disorders. PLoS One 7:e44017
Lin, Mingyan; Pedrosa, Erika; Shah, Abhishek et al. (2011) RNA-Seq of human neurons derived from iPS cells reveals candidate long non-coding RNAs involved in neurogenesis and neuropsychiatric disorders. PLoS One 6:e23356
Pedrosa, Erika; Sandler, Vladislav; Shah, Abhishek et al. (2011) Development of patient-specific neurons in schizophrenia using induced pluripotent stem cells. J Neurogenet 25:88-103

Showing the most recent 10 out of 19 publications